CAB-AXL-ADC + PD-1 Inhibitor for Lung Cancer

Recruiting in Palo Alto (17 mi)

+60 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: BioAtla, Inc.

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Eligibility Criteria

Adults over 18 with non-small cell lung cancer (NSCLC) who have measurable disease, are in good physical condition (ECOG status of 0 or 1), and expected to live at least three months. They must have proper blood, kidney, and liver function. Those with severe heart issues, prior specific cancer treatments, recent major surgery, uncontrolled brain metastasis, certain allergies or infections like HIV/hepatitis are excluded.

Inclusion Criteria

My kidneys are working well.

I am fully active or restricted in physically strenuous activity but can do light work.

Life expectancy of at least three months.

+4 more

Exclusion Criteria

I do not have uncontrolled brain metastases.

I have never had a severe allergic reaction to antibody treatments.

I am not pregnant or breastfeeding.

+4 more

Participant Groups

The trial is testing the safety and effectiveness of a new drug called CAB-AXL-ADC for NSCLC patients. It's being compared against PD-1 inhibitors which are a type of immunotherapy that helps the immune system fight cancer cells.

2Treatment groups

Experimental Treatment

Group I: CAB-AXL-ADC (BA3011)+PD-1 inhibitorExperimental Treatment2 Interventions

CAB-AXL-ADC (BA3011) with PD-1 inhibitor

Group II: CAB-AXL-ADC (BA3011)Experimental Treatment1 Intervention

CAB-AXL-ADC (BA3011) alone